Despite the interesting parallelism in aging and cancer recently reported with respect to 7 5 hypermethylated DNA regions, the relationship between hypomethylated DNA sequences in 7 6 these two processes has not been systematically studied. To address this issue, here we have 7 7 analysed DNA methylation changes and their associated chromatin patterns in a total of more 7 8 than 2,300 healthy and tumoral samples obtained from differentially aged individuals, using 7 9
HumanMethylation450 BeadChip data generated by The Cancer Genome Atlas (TCGA) 8 0 consortium and other datasets [23] [24] [25] . Our results confirmed the relationship between DNA 8 1 hypermethylation in aging and in cancer, but they also revealed important differences in DNA 8 2 hypomethylation changes in the two processes that might be important in order to understand 8 3 the possible role of DNA methylation as a molecular link between decline related to aging and 8 4 tumor development. 8 5
Results

6
DNA methylation profiling in aging and cancer 8 7
To identify DNA methylation changes in aging and cancer we collected DNA methylation data 8 8 obtained with the HumanMethylation450 BeadChip (Illumina) (see Methods) and compared the 8 9
DNA methylation status of a total of 361,698 CpG sites across 1,762 samples. These samples 9 0 corresponded to healthy and tumoral tissues obtained from differentially aged patients with 9 1 breast, kidney, thyroid, skin and brain tumors (see Table 1 and Additional file 2: Table S1 for 9 2 extended information). 9 3
Using an empirical Bayes moderated t-test (see Methods), we identified 113,314 autosomal 9 4
CpG sites that were differentially methylated (dmCpGs; FDR < 0.05) between breast tumor 9 5 samples and their corresponding non-tumorigenic counterparts (Fig. 1a ). Using a similar 9 6 approach, we identified 134,672 dmCpGs in tumors from kidney, 38,593 from thyroid, 205,143 9 7 from skin and 173,871 from brain tumors (Table 1 ; Fig. 1a , top panel and Additional file 3: 9 8 Table S2 ). Hierarchical clustering of samples using the tumor-type specific dmCpGs enabled us 9 9
to distinguish between tumoral and control samples ( Fig. 1b , upper panel; Additional file 1: 1 0 0 Figure S1 ). Although the number of significant hyper-and hypomethylated probes was 1 0 1 somewhat variable across the different tumor datasets, the magnitude of change was generally 1 0 2 similar and tumor-type independent, with no dominance of either hyper-or hypomethylation 1 0 3 changes. 1 0 4
We next studied age-associated DNA methylation changes in the same set of tissue samples. In 1 0 5 control cases, an empirical Bayes moderated t-test identified 2,588 autosomal dmCpG sites 1 0 6 (FDR < 0.05) between non-tumorigenic breast tissue obtained from young (ages ranging from 1 0 7 28-44 yrs) and elderly (aged between 75 and 90 yrs) donors. Using a similar approach, we 1 0 8 found 20,019 dmCpG sites in kidney tissues, 3,216 in equivalent thyroid tissues, 66,977 in skin 1 0 9 and 25,849 in brain tissues, obtained from young and elderly individuals (see Table 1 for age 1 1 0 ranges; Fig. 1a , middle panel and Additional file 3: Table S2 for additional information). 1 1 1
Hierarchical clustering of samples using the tissue-type specific dmCpGs enabled us to classify 1 1 2 most of the tissues according to their corresponding age groups (Fig. 1b , lower panel; 1 1 3 Additional file 1: Figure S1 ), but the efficiency of classification was reduced as compared to the 1 1 4 clustering obtained with the cancer dmCpGs. 1 1 5 Globally, methylation changes were found to be more pronounced in cancer than in aging ( Fig.  1  3  0 1c and Additional file 4: Table S3 , Wilcoxon tests; all P<0.05), while comparison of hyper-1 3 1 versus hypomethylation changes was variable and disease and tissue-type dependent. 1 3 2 Intriguingly, with the exception of thyroid cancer, most tumors obtained from differentially-1 3 3 aged patients did not show significant age-associated DNA methylation changes (Table 1, Fig.  1  3  4 1a, bottom panel and Additional file 3: Table S2 ). Further analyses of normal and cancer 1 3 5 samples with Horvath's predictor (implementation in wateRmelon R package) revealed that 1 3 6 thyroid cancer had the highest correlation of real-versus-predicted age across all the cancer 1 3 7 types in our dataset (Fig. 1d ). This result, which is in the same vein as previous observations 1 3 8
[26], suggests that thyroid tumors might be associated with a more conventional age-related 1 3 9 progression. 1 4 0 1 4 1
Genomic distribution of dmCpGs in aging and cancer 1 4 2
The study of the genomic distribution of the dmCpGs revealed that hypomethylated CpG sites 1 4 3 followed a similar disease and tissue-independent trend, being preferentially found at low 1 4 4 density CpG DNA regions interrogated by the array in both cancer and aging processes (average 1 4 5 hypomethylation signatures. When skin tissue was discarded from the analysis (Additional file 2 9 7 1: Figure S6 ) the observed over-enrichment disappeared in the case of DNA hypomethylated 2 9 8 probes, although it remained in the hypermethylation scenario (Fisher's tests, both P<0.001, 2 9 9 ORs = 0.8 and 3.0; EHMs = 5,357 and 7,568; JIs = 0.04 and 0.12, respectively), reinforcing the 3 0 0 observed overlapping differences between hyper-and hypomethylated probes. To determine the possible functional consequences and genomic coincidence of the different 3 0 4 histone marks of DNA hyper-and hypomethylation in aging and cancer, we performed an 3 0 5 enrichment analysis of NIH Roadmap and ENCODE Hidden Markov Model (HMM) defined 3 0 6 "chromatin states" across the same 98 human cell and tissue types used in the previous analyses 3 0 7 (see Methods). In total, eighteen states were used for the segmentation of the genome, which 3 0 8
were then grouped to highlight predicted functional elements. Figure S7 for tissue-specific signatures, and 3 1 4
Additional file 11: Table S10 for 98 full cell-and tissue-types). Color code indicates the 3 1 5 significant enrichment based on log2 odds ratio (OR). Common signatures are calculated from 3 1 6
hyper-and hypomethylated dmCpGs shared between 5 tissues for cancer (1,962 and 2,708 3 1 7 probes, respectively) or 3 tissues for aging (904 and 106 probes, respectively) (see Additional 3 1 8 file 7: Table S6 for CpG lists). b Panel indicating significant (P<0.05) transcription factor 3 1 9 enrichment at hyper-and hypomethylated dmCpG sites in aging and cancer that occurred in at 3 2 0 least 4 or 5 tissues (see Additional file 1: Figure S8 for tissue-specific results and Additional file 3 2 1 12: Table S11 for full data). Only the most representative transcription factors (those that 3 2 2 appeared as significantly over-enriched in at least 3 tracks or with an OR>3 in any track) were 3 2 3 selected for data representation. 3 2 4 3 2 5
As suggested by the earlier chromatin signature analyses, hypermethylated CpGs in both aging 3 2 6 and cancer were enriched in states associated with bivalent chromatin domains (i.e. those 3 2 7
formed by the combination of repressive histone mark H3K27me3 and activating histone marks 3 2 8
H3K4me3/1), polycomb repressive domains and repeat/ZNF genes. These patterns became 3 2 9 more evident when examining the dmCpGs shared by all five cancer tissues or at least three 3 3 0 aging tissues ( Fig. 5a ; see Additional file 1: Figure S7 for tissue-specific signatures and 3 3 1 Additional file 11: Table S10 for full data in all 98 cell-and tissue types). Hypomethylated CpG 3 3 2 sites in cancer were enriched in chromatin states associated with heterochromatin and 3 3 3 repeat/ZNF gene domains and, to a lesser extent, polycomb repressive domains. In contrast, 3 3 4 DNA hypomethylation in aging was primarily associated with chromatin states related to DNA 3 3 5 enhancers. Again, these marks were more pronounced in aging dmCpGs shared by at least three 3 3 6 tissues. As occurred with chromatin signatures, hypomethylation chromatin state differences 3 3 7
were weaker in skin and thyroid, albeit that the ratio of change of chromatin states always 3 3 8 followed the same behavior (data not shown). Collectively, these results support the notion that 3 3 9 DNA hypomethylation might have a different functional role in aging as compared to cancer. 3 4 0
In order to increase our understanding of the functional context of the chromatin signatures 3 4 1 characterized, we compared the dmCpG sites identified in this study with publicly available 3 4 2 ENCODE ChIP-seq data on transcription factor binding sites in 689 datasets corresponding to 3 4 3 188 transcription factors across 91 different cell types (see Methods) ( Fig. 5b ; see Additional 3 4 4 file 1: Figure S8 and Additional file 12: Table S11 for full tissue-specific results). As expected, 3 4 5 hypermethylated CpGs in aging and cancer were associated in all tissues with the presence of 3 4 6 EZH2 and SUZ12, components of the polycomb complex which directly deposits the 3 4 7
H3K27me3 mark. Interestingly, aging hypermethylation dmCpGs were specifically associated 3 4 8 with other types of transcription factors in various tissues, such as REST, HDAC2, RAD21, and 3 4 9 SETDB1. Transcription factor enrichment at hypomethylated dmCpG sites was more 3 5 0 heterogeneous than, but different from that of hypermethylated sites. Enrichment of similar 3 5 1 factors was found for cancer and aging, for example, EP300, FOS and JUN, among others. As 3 5 2 observed before, specific aging enrichment was found, such as GATA2/3. In this case, aging 3 5 3 hypomethylated dmCpG sites tended to display a more marked enrichment of most of the 3 5 4 cancer hypomethylation factors and, additionally, revealed the presence of other family-or 3 5 5 function related proteins, like FOSL1/2, MAFF, MAFK and STAT3. When examining 3 5 6 enrichment at common dmCpG sites shared by different tissues in cancer and aging, the initial 3 5 7 observations were further confirmed (Additional file 1: Figure S9 ). 3 5 8
We also performed gene and KEGG pathway ontology analyses ( Fig. 6a ; Additional file 13: 3 5 9 Table S12 ; see Additional file 1: Figure S10 for tissue-specific results). Hypermethylated CpGs 3 6 0 in both cancer and aging belonged to genes that were mainly related to developmental functions. 3 6 1
While genes containing hypomethylated CpGs in cancer were associated with extracellular 3 6 2 signaling, those for aging were, in general, much less enriched in any gene ontology. In the 3 6 3 case of KEGG pathways ( Fig. 6a ; Additional file 13: Table S12 and Additional file 1: Figure  3 6 4 S10), hypermethylated CpGs in both cancer and aging shared enrichment for several ontologies, 3 6 5 many related to cell metabolic and signaling pathways. In this respect, hypomethylated CpGs in 3 6 6 cancer had some ontologies in common while others were specific. Once again, aging 3 6 7 hypomethylated CpGs exhibited much less enrichment in any function. Panels indicating gene and KEGG pathway ontology enrichment for common hyper-and 3 7 1 hypomethylated dmCpGs shared between 5 tissues for cancer (1,962 and 2,708 probes, 3 7 2 respectively) or 3 tissues for aging (904 and 106 probes, respectively) (see Additional file 7: 3 7 3 Table S6 for CpG lists and Additional file 1: Figure S9 ). Color code indicates the significance 3 7 4 of the over-enrichment based on log10 P-value. Size of circles indicates gene ratio, calculated 3 7 5
as the ratio of number of identified hits with respect to the total number of components in a 3 7 6 CpGs also displayed a similar trend in kidney and skin analyses, data not shown). In order to exemplify the similarities and disparities observed for DNA methylation in aging 3 8 7
and cancer, we focused on a number of significant dmCpGs from two particular genomic 3 8 8 regions, located in chromosomes 11 and 16. (Fig. 6b and 6c ). We observed a substantial 3 8 9 correlation between bivalent posttranslational histone modifications, especially H3K27me3 and 3 9 0 H3K4me1/3, and presence of hypermethylated probes in aging and cancer. On the other hand, 3 9 1 DNA hypomethylated regions were more frequently located near H3K9me3 or H3K4me1 peaks 3 9 2 (bottom panel Fig. 6b and 6c) as outlined in our previous histone enrichment analyses. A 3 9 3 detailed inspection of the common genes with most abundant dmCpGs in aging and cancer 3 9 4 revealed a similar trend towards DNA hypermethylation at the boundaries of the gene PAX6 3 9 5 ( Fig. 6b, top panel) . Interestingly, a representative set of cancer cell lines, as well as fibroblasts 3 9 6 derived from patients with Hutchinson-Gilford progeria, also display higher levels of DNA 3 9 7 methylation when compared to normal cells in these differentially methylated regions ( Fig. 6b , 3 9 8 middle panel). On the contrary, the abovementioned pattern was mainly reversed in the case of 3 9 9
the RBFOX1 gene, located in a region which was preferentially hypomethylated in cancer ( and gene expression data. We initially performed differential gene expression analyses 4 0 8 comparing young versus old kidney tissue or normal versus tumoral kidney samples ( Fig. 7a , 4 0 9
Additional file 14: Table S13 ). These results allowed us to identify a total of 13 and 20,678 4 1 0 differentially expressed genes (DEGs) in aging and cancer conditions, respectively. The 4 1 1 majority of the aging DEGs were also found in cancer, including, for example, the CKM gene, 4 1 2 which contained a dmCpG in the proximity of its promoter ( Fig. 7b ), was differentially 4 1 3 expressed in both processes ( Fig. 7c ) and displayed a considerable negative correlation between 4 1 4 DNA methylation and gene expression in normal kidney (Spearman correlation = -0.37, Fig.  4 1 5 7d). To further explore the potential relationships between CpG methylation and gene 4 1 6 expression in these processes, and due to the reduced number of DEGs observed in the aging 4 1 7 context, we decided to perform all potential pairwise correlations between DNA methylation 4 1 8 and gene expression using cancer or aging related dmCpGs and genes expressed in a subset of 4 1 9 normal kidney tissue samples (n = 18). This approach enabled us to quantify the extent to which 4 2 0
CpGs whose methylation status changes in cancer and aging originally influence gene 4 2 1 expression in normal tissue. 4 2 2
We computed a total of 2.58e 09 and 3.84e 08 correlations between cancer and aging related 4 2 3 dmCpGs, respectively, and genes expressed in the normal KIRC dataset (Fig. 7e ). Despite the 4 2 4 considerable difference in number of dmCpGs between cancer and aging, when compared to the 4 2 5 total possible number of correlations, we found similar percentages of strong correlations 4 2 6 between DNA methylation and gene expression in both processes (Additional file 15: Table  4 2 7 S14). Moreover, these proportions were also higher than those observed when sampling random 4 2 8 probes from the array and computing their correlations (see Additional file 1: Figure S11 ). 4 2 9
These results indicate that both cancer and aging related dmCpGs are enriched in CpGs that can 4 3 0 influence, to some extent, gene expression in kidney tissue. 4 3 1
A more detailed inspection of the strongest correlations (>= 0.9 or <= -0.9) identified in these 4 3 2 datasets revealed that, in cancer, the number of unique dmCpG-gene pairs remained similar 4 3 3 (~20,000) regardless of the direction of the observed correlation (Fig. 7f, top) . Furthermore, 4 3 4 while the number of unique dmCpG-gene pairs in the aging context was much reduced 4 3 5 (~3,000), the proportion compared to the total number of strong correlations observed in a given 4 3 6
dataset remained, to a great extent, similar (Fig. 7f, bottom) . Interestingly, the differences 4 3 7
between the genomic distributions of the unique hyper-and hypomethylated -dmCpG-gene 4 3 8 pairs identified in aging or in cancer followed the same trend to those observed for the genomic 4 3 9 distribution of the hyper-and hypomethylated -dmCpGs identified in each of these processes 4 4 0 ( Fig. 2b-c <0.001 and <0.001, ORs = 2.2, 1.9, 1.6 and 1.7 for positively and negatively correlated dmCpGs 4 4 6 in aging and cancer, respectively) of the hypomethylated dmCpGs in both processes (Fig. 7g-h) . 4 4 7
It is worth noting that the distribution of the unique hypermethylated-dmCpGs which also 4 4 8 control gene expression was more enriched in open sea locations as compared to dmCpGs in 4 4 9 general in both aging and cancer ( Fig. 7g as compared to Fig. 2b ). 4 5 0
Finally, we compared the unique dmCpGs that displayed strong correlations between DNA 4 5 1 methylation and gene expression in aging or in cancer (Fig. 7i) . We observed an extensive 4 5 2 2 0 overlap between probes that displayed positive or negative correlations in the two processes 4 5 3 (Fisher's tests, all P<0.001, ORs = 908, 2244, 205, and 171; JIs = 0.57, 0.54, 0.57 and 0.54 for 4 5 4
aging and cancer hyper-and hypomethylated CpGs, respectively). This fact might explain their 4 5 5 similar genomic distributions ( Fig. 7g-h) , indicating that most of these dmCpGs could play a 4 5 6 dual role in the control of their different gene expression targets. We also observed a 4 5 7 considerable overlap between dmCpGs associated to gene expression identified in aging and 4 5 8 cancer processes (Fisher's tests, both P<0.001, ORs = 5.1 and 9.1; JIs = 0.06 and 0.03, for 4 5 9
hyper-and hypomethylated CpGs, respectively). Interestingly, regardless of whether the DNA 4 6 0 methylation change was towards hyper-or hypomethylation, ~ 60-70% of the aging-related 4 6 1 dmCpGs which controlled gene expression were also present in the group of cancer related 4 6 2 dmCpGs (Fig. 7i ). These results point towards similarities of cancer and aging related dmCpGs 4 6 3 in the control of gene expression in normal tissue, despite the fact that the number of cancer 4 6 4 related dmCpGs is clearly larger than their aging counterparts. Although it is widely accepted that cancer is an age-dependent disease, the underlying 4 9 1 molecular mechanisms are still poorly characterized. Interestingly, recent studies have proposed 4 9 2 that DNA methylation might play an important role in the tumorigenic process because genes 4 9 3 aberrantly hypermethylated in both aging and cancer are enriched in bivalent chromatin 4 9 4 domains and polycomb bound regions in embryonic stem cells [4] [5] [6] [9] [10] [11] . Loss of DNA 4 9 5 methylation at specific DNA regions has also been independently described in aging and cancer 4 9 6
[27]. However, it was unclear whether DNA hypomethylation also shared similar chromatin 4 9 7 signatures in both processes, something which is conceptually relevant to understanding the role 4 9 8 of 5 methylcytosine (5mC) as a possible molecular link between age decline and tumor 4 9 9 development. 5 0 0
In agreement with previously published data [11, 28] , we observed that the number of aging-and 5 0 1 cancer associated DNA methylation changes was variable and, in the case of aging, had a 5 0 2 marked tissue-type dependent component. In general, cancer displayed bidirectional changes 5 0 3 while, strikingly, hypermethylated CpG sites were predominantly observed for the aging 5 0 4 process. These results, which are ostensibly in contrast with the classically described global 5 0 5
hypomethylation changes in cancer and aging, might potentially arise from the limitations of 5 0 6 our study. As the methylation arrays used in our analyses mainly interrogate genetic elements 5 0 7 and do not include repeated DNA, which covers a substantial fraction of the genome and 5 0 8 frequently loses DNA methylation in tumors and aged cells, the genome-wide landscape may be 5 0 9 different [16, 27] . Nonetheless, epigenetic signatures have been successfully derived previously 5 1 0 using array technology [9] [10] [11] . Despite a careful normalization being applied for each of the 5 1 1 comparisons, slight deviations in the number of dmCpGs in particular tissues could be 5 1 2 influenced by the origin and type of the samples used in our statistical analyses, especially in the 5 1 3 case of glia and skin controls, since the data processed were obtained from a number of different 5 1 4 public databases. Furthermore, the changes in cell type composition that occur with age and 5 1 5 cancer are also well known confounding factors that could affect our datasets [29] . However, 5 1 6 the application of the SVA method of correction (and Houseman correction for blood) and the 5 1 7 use of a pure-cell dataset such as the glia dataset allowed us to tackle this issue in two different 5 1 8
ways [30] . Additionally, the use of the blood validation dataset [24] allowed us to verify the 5 1 9
reliability of our workflow, as in terms of whole blood dmCpGs we obtained 89% concordance 5 2 0 with previous studies using the same data [11] . 5 2 1
To compare the behavior of the DNA methylation changes in aging and cancer we first analysed 5 2 2 the genomic distribution of dmCpGs and, in line with previously published reports [31-34], we 5 2 3 found that hypomethylated CpGs were enriched at open sea DNA regions, principally those that 5 2 4
were intronic and intergenic, irrespective of the type of process. The distribution of 5 2 5
hypermethylated CpGs was found to be similar to that of the array, which is to a certain extent 5 2 6 to be expected because it was designed to interrogate a promoter-and CpG dense-biased portion 5 2 7 of the genome. Nonetheless, hypermethylation changes always occurred in far more CpG-dense 5 2 8
regions than hypomethylation changes [13, [32] [33] [34] . Our study allowed us to ascertain that the 5 2 9
observed effect was especially pronounced for aging dmCpGs. Very interestingly, while this 5 3 0 polarization in genomic location of hyper-and hypomethylated CpGs is more evident with 5 3 1 regards to the aging process, we found methylation changes to be much more pronounced in 5 3 2 tumor samples. This observation is compatible with previous descriptions of epigenetic clock 5 3 3 acceleration in cancer [26, 35] . 5 3 4
When studying the potential effect of tissue type on DNA methylation changes we found, in 5 3 5 agreement with recently published data [36] , that DNA methylation changes in different tumor 5 3 6 types were surprisingly similar, regardless of the tendency of the alteration. This observation is 5 3 7 conceptually relevant because it has classically been considered that different tumor types are 5 3 8 characterized by specific DNA methylation signatures [37, 38] , especially in the case of DNA 5 3 9
hypermethylation. In this sense, our data confirm that, although different tumor types might 5 4 0 display specific DNA methylation patterns, there is a significant common nexus between them.
4 1
The analysis of the DNA methylation changes observed with respect to the aging process also 5 4 2 revealed significant overlap between tissue types. It is possible that these results are affected by 5 4 3 the variability in the sizes of the sets of probes detected in the aging analysis, however, 5 4 4 everything considered, in this work both cancer and aging manifest tissue-independent changes 5 4 5 which could reflect core characteristics of each process. 5 4 6
Our data revealed that dmCpGs shared by two or more tissues were much less likely to have 5 4 7 different behaviors in other tissues, perhaps pointing towards non-stochastic and possibly 5 4 8 functional roles for these CpGs. Overall, there was still a large proportion of cancer 5 4 9
hypermethylated CpGs in a certain tissue that were able to be detected as hypomethylated CpGs 5 5 0 in other tumoral tissues, indicating that many of these CpGs have tissue-specific directional 5 5 1 changes that could be explained in two possible ways: a heterogeneous epigenome state in 5 5 2 which the affected sites suffer a stochastically directional drift, perhaps restricted by an initial 5 5 3 configuration in the original tissue [39, 40] ; or a functionally directional drift in which different 5 5 4 tumors acquire different epigenome-states that aid in cancer progression [41, 42] . 5 5 5
The systematic DNA methylation analyses described in this study confirm that DNA 5 5 6 hypermethylation in aging and cancer is associated with the same set of histone marks, 5 5 7
including the repressive H3K27me3 and H3K9me3 marks, and the activating H3K4me1/3 post-5 5 8 translational modifications. Chromatin-state analysis revealed that the hypermethylation-5 5 9 associated H3K27me3 and H3K4me1/3 marks configured bivalent chromatin domains, as has 5 6 0 been extensively described in embryonic stem cells [4] [5] [6] [9] [10] [11] . Moreover, our data reveal that 5 6 1 this chromatin signature is not restricted to only embryonic stem cells, but rather this trend 5 6 2 should be considered an extended, global tissue-independent chromatin signature of DNA 5 6 3 hypermethylation in aging and cancer. Interestingly, Chen and colleagues [36] have recently 5 6 4 demonstrated that normal-tissue signatures are better predictors of DNA hypermethylation 5 6 5 changes than ESC signatures. Furthermore, hypermethylation changes were also associated with 5 6 6 the repressive histone mark H3K9me3 [6, 43] , which was correlated to ZNF genes and DNA 5 6 7 repeats in our chromatin state analyses, and which might have a potential relationship with the 5 6 8 malignant transformation process [43, 44] . 5 6 9
Regarding DNA hypomethylation, our results showed that age-related DNA hypomethylation is 5 7 0 associated with the activating histone posttranslational modification H3K4me1, which supports 5 7 1 previously published data [11] . A slight tendency for enrichment of H3K27Ac, a histone mark 5 7 2 characteristic of active enhancers [45] , was also detected in our analyses. Intriguingly, the 5 7 3 chromatin signature of DNA hypomethylation in cancer was substantially different, with most 5 7 4
tumor types being primarily enriched in the posttranslational repressive histone modification 5 7 5
H3K9me3, a relationship that has been investigated in colon and breast cancer [46, 47] . This 5 7 6 observation might be conceptually relevant because DNA methylation has been proposed to be 5 7 7 a molecular link between aging and cancer [27, 48, 49] . However, our results suggest that the role 5 7 8 of DNA methylation as a possible link between aging and cancer is more complex than 5 7 9 previously proposed. Importantly, even though most of the observed DNA methylation changes 5 8 0 in aging were tissue specific, we were able to describe a common chromatin signature 5 8 1 characteristic of the aging process. This observation points towards the notion that there might 5 8 2 be non-stochastic underlying molecular mechanisms, and that these differ between aging and 5 8 3 cancer. 5 8 4
The different chromatin signatures of DNA hypomethylation in aging and cancer might have 5 8 5 important functional consequences. This was clearly evidenced by the analysis of the chromatin 5 8 6 states. Indeed, DNA hypomethylation in cancer was associated with heterochromatin DNA 5 8 7 regions, which is in line with previous work [31, 46] . It is curious that chromatin segmentation 5 8 8 analysis of chromatin states containing H3K9me3 revealed differing functionality of this mark 5 8 9 depending on whether it was associated with cancer and aging DNA hypermethylation (ZNF 5 9 0 genes and repeats) or simply DNA cancer hypomethylation (heterochromatin). 5 9 1 the outcome of interest respectively. The number of latent factors for each of the different 7 0 3 datasets was estimated using the "leek" method. 7 0 4 7 0 5
Differential DNA methylation analyses 7 0 6
Differentially methylated probes (dmCpGs) in aging and cancer were calculated with the 7 0 7 R/Bioconductor package limma (version 3.32.2) [72] . Briefly, a linear model between 7 0 8 methylation levels as response variable, the variable of interest (either age group or 7 0 9 sample_type) and the aforementioned surrogate variables was fitted for each of the analyses. For 7 1 0 the calculation of age related dmCpGs, samples (control or tumor) were divided into quantiles 7 1 1 in such a way as to obtain groups with sizes of n=15-30, and comparisons were performed 7 1 2 between the upper (OLD) and the lower (YOUNG) quantile. Cancer related dmCpGs were 7 1 3 calculated between normal tissue (Solid Tissue Normal) and tumor samples (Primary Tumor) as 7 1 4 indicated in Table 1 , Additional file 2: Table S1 and Additional file 3: Table S2 . 7 1 5
The set of p-values obtained from the tests was adjusted for multiple comparisons using the 7 1 6
Benjamini-Hochberg method to control for false discovery rate (FDR < 0.05). An additional 7 1 7 threshold of shift size was applied, filtering out significant probes with M-value changes of less 7 1 8 than 0.5, as has been suggested elsewhere [73] . 7 1 9
Venn diagram representations of all possible logical relationships between statistically 7 2 0 significant dmCpGs were generated with the online resource provided by the UGent/VIB 7 2 1 bioinformatics unit (available at http://bioinformatics.psb.ugent.be/webtools/Venn/). Further 7 2 2 enrichment analyses were performed by means of two-sided Fisher's tests (P<0.05 significance 7 2 3 threshold), measuring either effect size by odds ratio (OR), or the difference between observed 7 2 4 counts and expected hypergeometric means, employing appropriate backgrounds of interrogated 7 2 5 probes for the given context. For each of the probes in the HumanMethylation450 microarray, density of CpG was measured 7 2 8
as the number of CpGs present divided by the number of those possible in a 2 kbp window 7 2 9 3 0 centered on the CpG under study. Wilcoxon non-parametric tests were used to determine 7 3 0 whether there were significant difference between the density distributions of the CpGs 7 3 1 belonging to each subset of interest and the densities of the array probes in the background. A 7 3 2 significance level of 0.05 was employed for all tests. Shift size was measured using median 7 3 3 differences and Cliff's Delta (D) (see Additional file 5: Table S4) . Statistical significance with respect to concrete CGI status or genomic regions was determined 7 4 1 by two-sided Fisher's tests (significance level P<0.05), and ORs were used as a measure of the 7 4 2 association effect with respect to a particular feature (see Additional file 6: Table S5 ). the dataset of interest. Enrichment of histone marks was determined using histone ChIP-seq 7 5 1 peak tracks (H3K4me1, H3K4me3, H3K27me3, H3K36me3, H3K9me3 and H3K27ac marks) 7 5 2 from 98 epigenomes (primary tissues, cultures and cell lines) obtained from the NIH Roadmap 7 5 3 and ENCODE projects [76, 77] and integrated in the LOLA extended software (datasets obtained 7 5 4 from http://databio.org/regiondb) (see Additional file 9: Table S8 ). The same method was 7 5 5 employed for chromatin-segment analysis using NIH Roadmap's ChromHMM expanded 18-7 5 6 1 state model tracks for the same 98 epigenomes (see Additional file 1 Figure S7 and Additional 7 5 7 file 11: Table S10 , custom database generated with data obtained from 7 5 8 http://egg2.wustl.edu/roadmap/). In a similar fashion, ChIP-seq peak tracks from ENCODE for 7 5 9 transcription factor binding sites (TFBS) comprising 689 datasets corresponding to 188 TFs 7 6 0 analysed in 91 cell and tissue types were employed for TFBS enrichment analysis (datasets 7 6 1 integrated in LOLA core region database, http://databio.org/regiondb, see Additional file 12: 7 6 2 Gene and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway ontology enrichments 7 7 3 were calculated using the R/Bioconductor package missMethyl (version 1.8.0, gometh 7 7 4 function) [78] , which performs one-sided hypergeometric tests taking into account and 7 7 5 correcting for any bias derived from differing numbers of probes per gene interrogated by the 7 7 6 array (see Additional file 13: Table S12 ). The annotation databases that were interrogated are 7 7 7 http://www.kegg.jp/kegg/rest/keggapi.html for KEGG ontology, and the R/Bioconductor 7 7 8 package GO.db (version 3.4.1) for gene ontology purposes. Appropriate backgrounds of total 7 7 9 probes for each given context were employed in the corresponding analyses. The human data used in this study adhere to the ethical policies established by the TCGA 8 0 8 consortium (Ethics, Law and Policy Group), the National Cancer Institute (NCI) and the 8 0 9
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